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Abstract: Influenza virus affects the respiratory tract in humans causing a range of distinct manifestations including fever, nasal 
secretions, cough, headaches, muscle pain and pneumonia, which could become violent and severe. It was found that influenza A 
viruses remain resistant to amantadine and rimantadin with high level of oseltamvir resistance. Therefore, there is a need for constant 
improvement of drugs active against resistant influenza viruses. Propolis has anti-influenza activity both in vitro and in vivo. Human 
leukocyte interferon (HuIFN-αN3) is a multi-subtype protein that displays an antiviral activity against influenza virus. In this study 
we elucidated the anti-influenza activity of the mixes of water-soluble propolis (WSP) (Greit 120) and HuIFN-αN3 at different ratios. 
Greit 120 polyphenols, total phenol acids and bioflavonoid were characterized by HPLC-UV-ESI-MS504971 and HuIFN-αN3 by 
reverse-phase high-performance liquid chromatography (RP-HPLC). Influenza A and B viruses were separately added to the 
LLC-MK2 cells treated with WSP (Greit 120) and HuIFN-αN3 alone or in proportions 1:1, 1:2 and 2:1. Plates were incubated and 
cytopathic effect was determined. The best results (ID50) were obtained with the mix of 10% WSP and HuIFN-αN3 in proportion 1:2, 
showing ID50 at 12 ± 0.2 µg/mL and 19 ± 0.6 µg/mL for influenza A and B viruses, respectively. When comparing anti-influenza 
activity of WSP (Greit 120)/HuIFN-αN3 with that of ribavirin, it was found that 1:2 was the optimal ratio for WSP (Greit 
120)/HuIFN-αN3 (0.5 and 0.6 for influenza A and B, respectively). This new formulation of WSP (Greit 120) and HuIFN-αN3, 
showing better anti-Influenza activity, will definitely improve its application in flu infections. 
 
Key words: Water-soluble propolis, Greit 120, HuIFN-αN3, anti-influenza activity, ribavirin, ID50. 
 
1. Introduction 
Influenza virus affects the respiratory tract in 
humans and animals leading to a range of diverse 
symptoms, consisting of fever, nasal secretions, cough, 
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headache, muscle pain and pneumonia which usually 
could become severe [1, 2]. During influenza season, 
antigenic drift in the virus usually appears when the 
design of the year’s vaccine was then established. 
Therefore, the vaccine became less protective and 
outbreaks occur [3]. The pandemic avian H5N1 and 
H1N1 and then changed influenza virus A (H3N2) 
strains have expanded worldwide, so the emergence of 
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pathogenic influenza virus strains can be anticipated 
[4].  
It is noticed that most influenza A viruses remained 
resistant to amantadine and rimantadine with a high 
degree of oseltamivir resistance (but zanamivir 
sensitivity) in the seasonal wave of infection with 
H1N1 [5]. Therefore, a constant improvement of new 
anti-influenza virus drugs active against resistant 
influenza viruses is constantly required. 
As a folk medicine since 300 BC, bee propolis is 
used as a food supplement for maintenance or 
improvement of human health [6]. It is composed of 
resins (40%-55%), beeswax and fatty acids 
(20%-35%), essential oils (10%), pollen (5%) and 
other ingredients, such as minerals, vitamins and sugar. 
The chemical arrangement of propolis is complex and 
in it, over 180 compounds were determined. Among 
them, the polyphenols are most significant [7]. Its 
chemical composition differs, depending on origin and 
local plant ecology. Propolis’ pharmacological 
properties were accounted as anti-carcinogenic [8], 
anti-inflammatory [9] and anti-microbial [10]. The 
antiviral activity against several viruses [11] was 
further shown, e.g., adenovirus [12], HIV [13], herpes 
simplex virus [14, 15] and anti-influenza activity [16, 
17] both in vitro and in vivo.  
Human leukocyte interferon (HuIFN-αN3) is a 
multi-subtype protein showing antiviral, 
anti-proliferative, anti-tumor, radio-protective and 
anti-toxic activity. There are three main classes of 
IFNs, designated as Types I, II and III [18]. Type I 
includes IFN-α, IFN-β, IFN-δ, IFN-ε, IFN-ζ, IFN-κ, 
IFN-ν, IFN-τ, and IFN-ω. Type II is composed of a 
single cytokine, IFN-γ [19]. Types III is IFN-λ1, 
IFN-λ2, IFN-λ3 and IFN-λ4. Type I- and type 
III-IFNs with similar signal transduction systems stay 
linked to each other than type II-IFN [20]. It is applied 
to treat a variety of viral illnesses and cancers. Among 
viruses, there are influenza A and B being susceptible 
to low dosage of HuIFN-αN3 [21-23]. It is crucial to 
analyze the effectiveness of the combo of extract of 
propolis (EEP) and water-soluble propolis (WSP) 
(Greit 120) with HuIFN-αN3 and through this to 
improve their potential clinical usefulness. 
The purpose of the performed experiments was to 
elucidate the anti-influenza activity against influenza 
viruses A and B, of the combos of WSP (Greit 120) 
and HuIFN-αN3 in vitro. 
2. Materials and Methods 
2.1 Cells and Viruses 
LLC-MK2 cells were cultivated in the Eagle’s 
medium with 10% fetal calf serum (FCS) and 
antibiotics. Influenza A and B viruses’ different 
clinical isolates were from Virological Department of 
the Institute of Microbiology and Immunology of the 
Medical Faculty in Ljubljana (Slovenia). 
2.2 Compounds Employed in the Experiments 
The 10% WSP prepared from 30% WSP (Greit 120) 
was obtained from BNatural, Corbetta (Italy). And 
10% EEP was from Medex D.o.o., Ljubljana 
(Slovenia). HuIFN-αN3 was from Institute of 
Immunology, Zagreb (Croatia). 
2.3 Inhibition of Influenza A and B Viruses Evaluated 
with Plaque Reduction Assays 
Approximately 6  103 LLC-MK2 cells/well in 
Eagle’s medium + 10% FCS were seeded into 96-well 
plates, and incubated for 24 h at 37 °C in 5% CO2 
atmosphere. After reaching the confluence, the 
Eagle’s medium + 10% FCS were removed and on 
each plate from second to eleventh well were added 
100 μL of Eagle’s medium + 2% FCS. In the first well 
200 μL of: 10% EEP, 10% EEP + HuIFN-αN3 (1:1, 
1:2 and 2:1), 10% WSP (Greit 120), 10% WSP (Greit 
120) + HuIFN-αN3 (1:1, 1:2 and 2:1), 200 μL of 
HuIFN-αN3 and 200 μL of ribavirin as a control. All 
samples were serially diluted and incubated for 8 h at 
37 °C. Samples were added in two parallels and three 
replicates. Then, medium with samples was removed 
and influenza A and separately influenza B viruses 
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(100 μL/well) were added and plates incubated at 
37 °C for 24 h in 5% CO2 atmosphere, when in the 
control 100% cytopathic effect (CPE) with small 
plaques were established. The plates with 
treated/infected LLC-MK2 cells were rinsed with 
phosphate-buffered saline (PBS), fixed with 5% 
glutaraldehyde, washed further with PBS and to them 
100 μL of crystal violet was added for twenty minutes. 
With PBS, washed plates were air-dried and measured 
at 570 nm. The effective concentrations for ID50 were 
determined from a curve relating the plaque number to 
the concentrations of the propolis extracts and 
HuIFN-αN3 [24, 25]. Effect of various combinations 
of EEP or WSP (Greit 120) with HuIFN-αN3 in 
different combinations (1:1, 1:2 and 2:1) on influenza 
A and B viruses was further expressed as a ratio to 
ribavirin [26] by Eq. (1): 
(1) 
2.4 Analysis of HuIFN-αN3 by RP-HPLC 
The HuIFN-αN3 subtype composition was analyzed 
by reverse-phase high-performance liquid 
chromatography (RP-HPLC). Used HPLC column was 
Phenomenex, Aeris™ Peptide column 3.6 μm XB-C18, 
250  4.6 mm. On it, different HuIFN-α samples 
(natural and recombinant) by approximately one 
million of antiviral units (AU/mL) in a volume of 20-40 
μL were put on the column. Adsorbed, were eluted by 
the linear gradient of solvent A (distilled water + 0.1% 
of trifluoroacetic acid (TFA)) and solvent C 
(acetonitrile + 0.1% TFA) for 20 min with a flow rate 
of 0.8 mL/min and pressure of 139-140 bars. The 
courses of RP-HPLC chromatography of different 
HuIFN-αN3 samples are shown in Table 1. 
Temperature of the column was 40 °C. The absorbance 
was measured at 214 nm and 280 nm. HuIFN-αN3 
species of different compositions separated agreeing to 
the fact that there is relative hydrophobic pattern using 
RP-HPLC [27, 28]. 
2.5 The Detection of Pinocembrin and Galangin by 
RP-HPLC Method 
In 10 mL burette, 1.0 mg of pinocembrin or 
galangin were put and diluted to 10.0 mL with 
methanol. From this solution, 150 μL of the samples 
were transferred into a vial and loaded with 1.350 µL 
of methanol. Samples filtered through a 0.45 μm filter 
were injected by 20 μL into the HPLC column. In the 
experiments HPLC column Purospher® STAR RP-18 
5 μm, 150  4.6 mm was used. The conditions of the 
HPLC procedure: (a) temperature of the column: 
25 °C; (b) flow: 0.7 mL/min; (c) pressure: 90-100 Bar; 
(d) ate: 62.5; (e) absorbance: 290 nm; (f) injection 
volume: 20 μL; (g) gradient: solvent A (distilled water 
+ 1% formic acid), solvent C (acetonitrile) [29]. Steps 
of various HPLC runs are presented in Table 2. 
2.6 Statistical Analysis 
The ID50 based on the mean plaque number was 
calculated on the raw data of an in-triplicate assay by 
regression analysis using Probit (SPSS statistical 
software package), determining the concentration of 
drug required to reduce the number of plaques by 50%. 
Statistical analysis of the experimental data was 
performed with a two-tailed Student’s t-test for paired 
samples with a p = 0.05 as the smallest level of 
significance. 
 
Table 1  Time course of RP-HPLC chromatography of different HuIFN-αN3 samples.  
Step: chromatography of different IFN samples in step Time (min) Solvent A (%) Solvent C (%) 
0 0 91 9 
1 3 80 20 
2 6 50 50 
3 12 50 50 
4 15 91 9 
5 20 91 9 
 
 
Ribavirin ID50 index = 
Propolis’ extract and/or 
HuIFN-αN3 (1:1, 1:2, 2:1) ID50
Ribavirin ID50 
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Table 2  The steps of the RP-HPLC detection of pinocembrin and galangin.  
Step: Chromatography of pinocembrin and galangin step Time (min) Solvent A (%) Solvent C (%) 
0 0 70 30 
1 5 60 40 
2 15 60 40 
3 20 35 65 
4 25 35 65 
5 30 70 30 
6 35 70 30 
 
3. Results 
3.1 RP-HPLC Analyses of Sendai Virus (Cantell Strain) 
Induced Interferon (HuIFN-αN3) 
HuIFN-αN3 subtypes in different samples (natural 
or recombinant) are separated according to its relative 
hydrophobicity using HPLC column Purospher® 
STAR RP-18 5 μm. The separation of different 
HuIFN-αN3 subtypes in the samples was achieved by 
increasing acetonitrile concentration [29, 30]. The 
least hydrophobic interferon subtypes were eluted as 
early peaks and the most hydrophobic Interferon 
subtypes eluted as later. As standards, different 
human recombinant interferons α was used: 
HuIFN-αA, HuIFN-α2a and HuIFN-α2b. Their 
chromatograms and the chromatograms at 280 nm of 
the Russian HuIFN-αN3 (NDV induced) and 
HuIFN-αN3 of Institute of Immunology Zagreb 
(Croatia) were used as standards (Fig. 1A). The 
positions of different HuIFN-αN3 subtypes were 
determined according to the 214 nm chromatogram in 
comparison to the protein profile measured at 280 nm. 
The predominant components of the Sendai virus 
induced HuIFN-αN3, are shown in Fig. 1B, and are 
natural IFN subtypes: α1, α2, αA, α2b and α14. The 
most important is the relative ratio between α1 and α2 
(values of mAU relative units) [30]. Various types of 
HuIFN-αN3 inductors differ in induction capacity of 
IFN subtypes: α1, α2, αA, α2b and α14. The 
HuIFN-αN3 subtype’s antiviral activity in IU/mL was 
determined by the detection of their antiviral activity 
according to the standard procedure: Monolayer 
received interferon dilution at two-fold increasing 
levels overnight. The following morning, the medium 
was removed and 100 μL of challenge virus (vesicular 
stomatitis virus) in Eagle’s medium + 2% FCS were 
added, and the cell layers were examined in a 
microscope 24 h later and scored (+4, +3, +2, +1, +0 
corresponding to 100% destruction, 75%, 50%, 25%, 
non-infected, respectively) [31] (Table 3).  
3.2 Quantity of Caffeic Acid, Crysin, Pinocembrin and 
Galangin in 10% EEP 
The 1.0 mg of caffeic acid, crysin, pinocembrin and 
galangin were put and diluted to 10.0 mL with 
methanol. From this solution, 150 μL of the sample 
was transferred into a vial and loaded with 1.350 μL 
of methanol. Samples filtered through a 0.45 μm filter 
were injected by 20 μL into the HPLC column 
Purospher® STAR RP-18 5 μm. Their separation was 
achieved with acetonitrile gradient in HPLC column 
(Fig. 2A). The 10% EEP was analyzed under the same 
conditions in the Purospher® STAR RP-18 5 μm 
HPLC column. Its separation measured at 290 nm, 
with acetonitrile gradient is presented in Fig. 2B [32]. 
The quantity of caffeic acid, crysin, pinocembrin and 
galangin in the experimental sample of 10% EEP was 
calculated in comparison to standards (Fig. 2A). 
Therefore, Table 4 indicates the quantity of caffeic 
acid, crysin, pinocembrin and galangin in the 10% 
EEP. 
3.3 Molecular Composition of WSP (Greit 120) 
Determined by HPLC-UV-ESI-MS 504971 
Fig. 3 shows the HPLC-UV-ESI-MS504971 profile 
of WSP (Greit 120). 
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Fig. 1  RP-HPLC profiles of the Sendai virus-induced HuIFN-αN3. 
(A) SV = Sendai virus (Cantell strain). Protein profiles of the various IFNs at 280 nm; (B) protein profile at 280 nm ( ) and 
IFN profile at 214 nm ( ) of HuIFN-αN3 induced with 100 HA/mL of Sendai virus (Cantell strain). 
 
 
Fig. 2  RP-HPLC profile of the bio-flavonoid’s standards (caffeic acid, crysin, pinocembrin and galangin) (A); the RP-HPLC 
profile of 10% EEP (Medex d.o.o., 1000 Ljubljana, Slovenia) (B).  
 
Table 3  The subtype composition of the Sendai virus (Cantell strain) induced HuIFN-αN3. 
No. HuIFN-αN3 subtype IU/mL 
1 αA 22.430 
2 α2b 11.000 
3 α1 44.280 
4 α2 11.750 
5 α6 1.280 
6 α8 1.800 
7 α13 1.800 
8 α14 3.500 
 Complete HuIFN-αN3 100.000 
 
4,000 
 
3,000 
 
2,000 
 
1,000 
 
4,000 
 
3,000 
 
2,000 
 
1,000 
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Table 4  Quantity of caffeic acid, crysin, pinocembrin and galangin in 10% EEP.  
Extract Caffeic acid 
(μg/mL) 
Crysin 
(μg/mL) 
Pinocembrin 
(μg/mL) 
Galangin 
(μg/mL)  
10% EEP 19 ± 0.18 5.4 ± 0.48 0.32 ± 0.08 0.29 ± 0.11 
 
 
Fig. 3  HPLC-UV-ESI-MS504971 of flavonoid’s profile of an average sample of WSP (Greit 120).  
1 = phenolic acids (caffeic, coumaric, ferulic, isoferulic); 2 = quercetin; 3 = pinobanksin 5-methyl ester; 4 = quercetin 3-methyl ester; 
5 = pinobanksin; 6 = apigenin; 7 = kaempferol; 8 = isorhamnetin; 9 = luteolin 5-methyl ester; 10 = quercetin 5-7-dimethyl ester; 11 = 
galangin 5-methyl ester; 12 = quercetin 7-methyl ester; 13 = chrysin; 14 = pinocembrin; 15 = galangin; 16 = pinobanksin-3-O-acetate; 
17 = CAPE; 18 = metoxychrysin; 19 = pinobanksin-3-O-propionate; 20 = caffeic acid cinnamyl ester; 21 = pinobanksin-3-O-butyrate; 
22 = pinobanksyn-3-O-pentenoate; 23 = other pinobanksin derivative; 24 = pinobanksin-3-O-hexanoate; 25 = other pinobanksin 
derivative. 
 
In Table 5, the molecular composition of WSP 
(Greit 120) in a very precise way is shown.  
3.4 Antiviral Activity of Combinations of 10% EEP, 
10% WSP (Greit 120) and HuIFN-αN3 
The experiments were performed to analyze the 
anti-influenza activity of 10% WSP (Greit 120) and 
10% EEP in combination with HuIFN-αN3 in various 
proportions (1:1, 1:2 and 2:1). Ribavirin alone was a 
control. The results in Table 6 showed that the best 
results for ID50 were, when the combination of 10% 
WSP (Greit 120) and HuIFN-αN3 in ratio 1:2 was 
used (ID50 12 ± 2 μg/mL for influenza A and 19 ± 6 
μg/mL for influenza B). With 10% EEP and 
HuIFN-αN3, the best ratio was the same 1:2, where 
 
 
it was 22 ± 7 μg/mL for influenza A and 15 ± 4 
μg/mL for influenza B (Table 7). 
3.5 Ribavirin ID50 Index 
Ribavirin ID50 index was calculated to compare the 
ID50 (antiviral activity) of WSP (Greit 120) or 10% 
EEP in combination with HuIFN-αN3 in ratios 1:1, 
1:2 and 2:1 in comparison to ribavirin. The results are 
in Tables 8 and 9 and Figs. 4 and 5. The lower is, the 
better it is. The ratio 1:2 was still the best with WSP 
(Greit 120) in combination with HuIFN-αN3 (0.5 for 
influenza B and 0.6 for influenza A virus). With EEP 
in combination with HuIFN-αN3, the best was the 
same ratio 1:2 (0.7 for influenza B and 1.3 for 
influenza A virus). 
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Table 5  The molecular composition of WSP (Greit 120) determined by HPLC-UV-ESI-MS504971. 
Number on chromatogram Polyphenols species Greit 120 (% w/v) 
1 Phenolic acids (caffeic, coumaric, ferulic, isoferulic) 0.5 
2 Quercetin 1.5 
3 Pinobanksin 5-methyl ester 1.4 
4 Quercetin 3-methyl ester 5.0 
5 Pinobanksin 4.0 
6 Apigenin 1.1 
7 Kaempferol 3.8 
8 Isorhamnetin 3.3 
9 Luteolin 5-methyl ester 2.1 
10 Quercetin 5-7-dimethyl ester 1.7 
11 Galangin 5-methyl ester 1.1 
12 Quercetin 7-methyl ester 3.2 
13 Chrysin 5.0 
14 Pinocembrin 2.9 
15 Galangin 7.5 
16 Pinobanksin-3-O-acetate 9.5 
17 CAPE 0.3 
18 Metoxychrysin 1.1 
19 Pinobanksin-3-O-propionate 1.2 
20 Caffeic acid cinnamyl ester 0.2 
21 Pinobanksin-3-O-butyrate 5.7 
22 Pinobanksyn-3-O-pentenoate 2.6 
23 Other pinobanksin derivative 0.7 
24 Pinobanksin-3-O-hexanoate 0.3 
25 Other pinobanksin derivative 0.4 
26 Other pinobanksin derivative 3.3 
27 Other pinobanksin derivative 0.5 
28 Other pinobanksin derivative 0.2 
29 Other pinobanksin derivative 0.7 
Total identified polyphenols 70.8 
Phenolic acids and derivatives 1.0 
Flavones and flavonols 36.4 
Flavanones and dihydroflavonoles 33.4 
Source: Data were kindly provided by Prof. Dr. Nicola Volpi (Department of Life Sciences, University of Modena & Reggio Emilia, 
Modena 41125, Italy). 
 
Table 6  Antiviral activity of 10% WSP (Greit 120) and HuIFN-αN3 in the ratios 1:1, 1:2 and 2:1 expressed as ID50 in 
μg/mL. 
Viruses 10% WSP  (Greit 120) 
ID50 
inhibition 
+ HuIFN- 
αN3 (1:1) 
ID50 
inhibition
+ HuIFN-
αN3 (1:2)
ID50 
inhibition
+ HuIFN-
αN3 (2:1)
ID50 
inhibition Ribavirin 
ID50 
inhibition
Influenza A 31 ± 9 - 22 ± 2 9.7 12 ± 2 19.7 25 ± 6 6.3 20 ± 2 11.7 
T-test   0.54  1.08  0.31  0.63  
Influenza B 31 ± 3 - 29 ± 2 2.1 19 ± 7 11.6 30 ± 2 1.10 28 ± 3 3.1 
T-test   0.08  0.26  0.05  0.08  
ID50 = Concentration of sample needed to reduce the virus-induced CPE to 50%. 
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Table 7  Antiviral activities of 10% EEP and HuIFN-αN3 in the ratios 1:1, 1:2 and 2:1 expressed as ID50 in μg/mL. 
Viruses 10% EEP ID50 inhibition 
+ HuIFN- 
αN3 (1:1) 
ID50 
inhibition
+ HuIFN-
αN3 (1:2)
ID50 
inhibition
+ HuIFN-
αN3 (2:1) 
ID50 
inhibition Ribavirin 
ID50 
inhibition
Influenza A 82 ± 11 - 35 ± 7 46.41 22 ± 8 59.31 42 ± 4 39.71 20 ± 2 61.91 
T-test   0.67  0.87  0.58  0.97  
Influenza B 62 ± 6 - 31 ± 6 31.00 15 ± 6 47.00 31 ± 7 30.90 28 ± 2 34.40 
T-test   0.51  0.83  0.49  0.62  
ID50 = Concentration of sample needed to reduce the virus-induced CPE to 50%.  
 
Table 8  Ribavirin ID50 index: Comparison of ID50 activity of 10% WSP (Greit 120) in combination with HuIFN-αN3 in 
ratios 1:1, 1:2 and 2:1 to ribavirin. 
Viruses 10% WSP (Greit 120) + HuIFN-αN3 (1:1) + HuIFN-αN3 (1:2) + HuIFN-αN3 (2:1) 
Influenza A 1 ± 0.05 1 ± 0.09 0.6 ± 0.04 1 ± 0.02 
T-test  -0.45 -0.9 0.73 
Influenza B 1 ± 0.10 1 ± 0.03 0.6 ± 0.09 1 ± 0.06 
T-test  0.76 -0.83 0.39 
 
Table 9  Ribavirin ID50 index: Comparison of ID50 activity of 10% EEP in combination with HuIFN-αN3 in ratios 1:1, 1:2 
and 2:1 to ribavirin.  
Viruses 10% EEP + HuIFN-αN3 (1:1) + HuIFN-αN3 (1:2) + HuIFN-αN3 (2:1) 
Influenza A 4 ± 0.65 1 ± 0.76 1 ± 0.12 2 ± 0.9 
T-test  -0.08 0.9 0.94 
Influenza B 2 ± 0.22 1 ± 0.12 0.5 ± 0.05 1 ± 0.12 
T-test  0.48 -0.53 0.48 
 
 
Fig. 4  Ribavirin ID50 index of WSP (Greit 120) and/or combination with HuIFN-αN3 in ratios 1:1, 1:2 and 2:1. 
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Fig. 5  Ribavirin ID50 index of EEP and/or combination with HuIFN-αN3 in ratios 1:1, 1:2 and 2:1. 
 
4. Discussion 
The samples of very detailed analyzed WSP (Greit 
120) (Table 4) containing different polyphenols: 
apigenin (ID50 8.1 ± 4.7 μg/mL), chrysin (ID50 > 100 
μg/mL), kaempferol (ID50 24.8 ± 4.3 μg/mL), 
quercetin (ID50 > 100 μg/mL) and caffeic acid (ID50 
49.7 ± 5.0 μg/mL) already showed anti-influenza 
activity in vitro [33]. The anti-influenza A and B virus 
activity of complete WSP (Greit 120) molecule is: 
ID50 31 ± 0.9 μg/mL for influenza A virus and ID50 29 
± 0.2 μg/mL for influenza B virus, what is bit lower, 
but comparable with ribavirin, having ID50 20 ± 0.2 
μg/mL for influenza A and ID50 28 ± 0.4 μg/mL for 
influenza B. When HuIFN-αN3 is added to Greit 120 
in ratio 1:1, the ID50 22 ± 0.2 μg/mL for influenza A 
and 31 ± 0.3 μg/mL for influenza B are found. When 
this ratio is 1:2, the ID50 is 12 ± 0.2 μg/mL for 
influenza A and 19 ± 0.7 μg/mL for influenza B virus. 
The ratio 2:1 shows the ID50 25 ± 0.6 μg/mL for 
influenza A and 30 ± 0.2 μg/mL for influenza B. The 
highest increase was found when WSP (Greit 120) is 
combined with HuIFN-αN3 in ratio 1:2. To elucidate 
out the mechanisms of anti-influenza activity of WSP 
(Greit 120) it was found that caffeic acid from it could 
restore the viability of cells infected with influenza 
virus in a dose dependent manner [34]. To find 
working mechanisms of this anti-influenza activity, it 
was measured the relative value of influenza virus 
RNA in cultured cells with and without antiviral 
compounds. It was found that the relative value of 
influenza virus RNA/viable cells was not significantly 
different between groups with different compound 
concentration. So it is possible that WSP (Greit 120) 
has no direct influence on an influenza virus or does 
not interact with influenza virus components, although 
Li et al. [35] reported that caffeoylquinic acid from 
WSP (Greit 120) binds to the gp120 of RSV 
(respiratory syncytial virus) and inhibits virus-cell 
fusion events in the early stage of the replication cycle. 
Thus, the anti-influenza activity of WSP (Greit 120) is 
not derived from an inhibition of virus replication, as 
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is true for a neuraminidase inhibitory drug, but may be 
due to another mechanism, such as an enhancement of 
cell resistance. As to the effect on antiviral executor 
genes, WSP (Greit 120) enhanced myxovirus 
resistance 1 (Mx1) expression [36]. Different 
specificities in antiviral effects of HuIFN-αN3 against 
influenza A and B viruses were reported as in vitro 
and in vivo [37]. They share the same specific cell 
receptor, interferon type I receptor (IFN-αR) 
composed of two subunits, IFN-αR1 and IFN-αR2, 
and interact with its different regions [38]. Antiviral 
activity of HuIFN-αN3 against influenza A, B and C 
viruses is mediated, at the least in part, by the 
induction of intracellular antiviral proteins, such as 
MxA protein. It is induced by HuIFN-αN3 as a whole 
and inhibits the replication of various influenza 
viruses [39, 40]. 
WSP (Greit 120) enhances the anti-influenza 
activity of HuIFN-αN3 in dose-dependent ratio via 
enhanced resistance 1 (Mx1) expression and MxA 
induction of influenza virus replication inhibition. 
5. Conclusions 
From the performed experimental study, the 
following conclusions may be drawn. The 
anti-influenza A and B activity of WSP (Greit 120) is 
ID50 31 ± 0.9 μg/mL for influenza A virus and ID50 29 
± 0.2 μg/mL for influenza B. It is bit lower, but 
comparable with ribavirin, having ID50 20 ± 0.2 
μg/mL for influenza A and ID50 28 ± 0.4 μg/mL for 
influenza B.  
Combining WSP (Greit 120) with HuIFN-αN3 in 
ratio 1:2 caused the highest increase of anti-influenza 
A and B viruses’ activity in vitro. 
Anti-influenza activity of the combination of WSP 
(Greit 120) with HuIFN-αN3 is higher against 
influenza B than against influenza A virus. 
This new formulation of WSP (Greit 120) and 
HuIFN-αN3 showing better anti-influenza activity, 
will definitely improve its application in flu 
infections. 
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